The Medical Takeaways from Stephen A. Smith's GLP-1 Story

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for The Medical Takeaways from Stephen A. Smith's GLP-1 Story

At a glance

| Item | Detail | |---|---| | Confirmed use | Yes, publicly discussed on First Take | | Drug class | GLP-1 receptor agonist | | Confirmed specific drug | Not publicly specified | | Clinical goal (stated) | Weight management, general health | | Public platform | ESPN First Take, on-camera discussions | | HealthRX take | High-visibility case with direct public-health implications |

What Stephen A. Smith Has Actually Said

Stephen A. Smith confirmed on ESPN's First Take that he has used a GLP-1 medication as part of his health regimen. He discussed the effect the medication had on his appetite and overall physical condition during on-air segments, making the disclosure in a conversational, matter-of-fact way rather than as a formal announcement.

He did not publicly name a specific drug within the GLP-1 class, so assigning a particular agent (semaglutide, tirzepatide, liraglutide, or any other) would be speculation. The HealthRX Medical Team will not do that. What Smith confirmed is the drug class, not the molecule.

His openness is, by any measure, medically significant at a population level. Smith commands a large, predominantly male sports audience, a demographic that is underrepresented in preventive care engagement and that carries disproportionate rates of obesity-related cardiovascular risk. When a public figure in that cultural space describes, without apparent embarrassment, that he is using a prescription medication to manage his weight, the downstream effect on health-seeking behavior in that audience is not trivial.

What GLP-1 Receptor Agonists Actually Are

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced primarily in the L-cells of the small intestine in response to nutrient ingestion. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety through both peripheral and central nervous system pathways.

Synthetic GLP-1 receptor agonists were originally developed for type 2 diabetes management. The first approved agent, exenatide, reached the market in 2005. The class expanded significantly when semaglutide, at the higher 2.4 mg weekly subcutaneous dose, received FDA approval in June 2021 specifically for chronic weight management under the brand name Wegovy, marking a formal expansion of the class beyond glycemic control.

Tirzepatide (Zepbound) added a dual GIP/GLP-1 mechanism and received FDA approval for obesity in November 2023. These are not "diet pills" in any colloquial sense. They are receptor-level pharmacological agents with a specific mechanistic basis and a growing body of outcomes data.

The Clinical Evidence: What These Drugs Produce

The STEP 1 trial, published in the New England Journal of Medicine in 2021, remains one of the most cited benchmarks. Participants receiving semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group. That is a meaningful difference, but "mean" is the operative word. Individual response varies substantially.

The SURMOUNT-1 trial for tirzepatide, published in NEJM in 2022, showed even larger average losses: up to 22.5% at the highest dose studied (15 mg weekly). Some participants lost considerably more; others lost considerably less.

What does this mean for a patient watching Stephen A. Smith discuss his results on television? It means the population average is real, but the individual trajectory is not guaranteed. Factors including baseline weight, genetic GLP-1 receptor sensitivity, concurrent dietary behavior, activity level, and medication adherence all shape the actual outcome for any given person.

The HealthRX Medical Team emphasizes this point directly: celebrity outcomes are not clinical benchmarks. A public figure with personal trainers, nutrition support, and a structured schedule will often show results that outpace what an average patient achieves on the same medication class.

Side-Effect Realities: The Conversation Smith's Disclosure Invites

Smith's public discussion touched on his experience with the medication's appetite-suppressing effects. The clinical literature is equally clear about the side-effect profile that accompanies those effects.

Gastrointestinal adverse events are the most common reason for dose reduction or discontinuation. In STEP 1, nausea affected approximately 44% of semaglutide participants, vomiting affected 24%, and diarrhea affected 30%. Most of these events were described as mild to moderate and were concentrated in the dose-escalation phase, typically the first 16 to 20 weeks of treatment. FDA prescribing information recommends a slow titration schedule specifically to mitigate this.

More serious but rarer concerns include:

  • Pancreatitis. Cases have been reported. The FDA label carries a warning. Patients with a personal or family history of pancreatitis or medullary thyroid carcinoma require careful risk-benefit discussion before starting any GLP-1 agent.
  • Gallbladder disease. Rapid weight loss by any mechanism increases cholelithiasis risk. A 2022 analysis in JAMA Internal Medicine found higher rates of gallbladder-related adverse events with semaglutide compared with placebo.
  • Muscle mass loss. This is an underappreciated and clinically important concern. GLP-1-mediated weight loss is not purely fat. Studies have documented lean mass reductions alongside fat mass reductions, with the ratio varying by patient and activity level. Resistance training during treatment is not optional for patients who care about long-term metabolic health; it is clinically advisable.
  • Psychiatric symptoms. The FDA added a monitoring note for mood-related changes after postmarket reports. This does not constitute a black-box warning but warrants attention, particularly in patients with prior mood disorder history.

What Happens When a Patient Stops: The Discontinuation Reality

This is the clinical chapter that is almost always absent from celebrity media coverage, and it may be the most important one.

The STEP 4 trial, published in JAMA in 2022, specifically examined what happens when semaglutide is discontinued after 20 weeks of treatment. Participants who switched to placebo regained approximately two-thirds of the weight they had lost within 48 weeks after stopping. Cardiometabolic risk markers that had improved during treatment also partially reversed.

This finding has a straightforward mechanistic explanation. GLP-1 receptor agonists work while they are present in the body. They do not permanently alter the set-point physiology, the adipose tissue signaling, or the hypothalamic appetite regulation that contributes to weight regain after loss. When the drug is withdrawn, those biological drives reassert themselves.

The HealthRX Medical Team notes that this does not make GLP-1 medications less valuable. It makes them more analogous to antihypertensive or lipid-lowering therapy than to a finite "treatment course." Most patients who benefit from these agents should anticipate long-term, potentially indefinite use if the goal is durable weight maintenance. Prescribing clinicians have an obligation to communicate this clearly before a patient starts therapy, not after they have already achieved results and are considering stopping.

Whether Stephen A. Smith has continued, paused, or modified his GLP-1 use is not publicly confirmed. The HealthRX Medical Team will not speculate on his current status.

Dose-Response Patterns: Why Starting Dose Is Not the Therapeutic Dose

Public conversations about GLP-1 medications rarely explain the titration structure. These drugs are initiated at a low dose and escalated on a defined schedule over weeks to months. For semaglutide (Wegovy), the standard schedule moves from 0.25 mg weekly to the 2.4 mg maintenance dose over approximately 16 to 20 weeks. For tirzepatide (Zepbound), escalation from 2.5 mg to the highest doses can span a similar period.

This matters because patients who experience disappointing results at the starting dose are not necessarily non-responders. They may simply be at a sub-therapeutic dose. A dose-response analysis from the STEP program confirmed that weight loss outcomes scaled with dose across the titration range.

Conversely, patients who tolerate a lower dose poorly, due to gastrointestinal symptoms, may need to hold at an intermediate dose for a longer period rather than accelerating the schedule. The titration is not a formality; it has a real pharmacological rationale.

The Broader Public-Health Lesson From High-Profile Disclosure

Smith is not the first public figure to discuss GLP-1 use. Several celebrities across entertainment and sports have discussed or are speculated to have used agents in this class. But Smith's case has particular resonance because of his audience demographics, his candor about it being a medical tool rather than a lifestyle accessory, and the setting: a sports debate show watched by millions of people who may have never had a direct conversation with a physician about weight-management pharmacotherapy.

Research published in the Journal of the American Medical Association has documented that celebrity health disclosures influence both patient-level health behavior and media coverage of related conditions. That influence can cut both ways. A disclosure can motivate appropriate care-seeking, or it can create unrealistic expectations about speed, magnitude, and permanence of results.

The HealthRX Medical Team's position is that Smith's disclosure is net-positive for public health literacy, precisely because his on-air discussion was relatively grounded. But any patient inspired by his account should enter a clinical conversation with their prescriber armed with the full picture: realistic average outcomes from the trial data, a complete side-effect inventory, a clear understanding of the discontinuation physiology, and an honest assessment of what concurrent lifestyle investment is required to optimize results.

GLP-1 receptor agonists are among the most efficacious pharmacological weight-management tools ever studied. They are also not magic. The Stephen A. Smith conversation is most useful not as a celebrity endorsement, but as a starting point for a much longer and more specific discussion between a patient and a physician.

Frequently asked questions

›
›
›
›
›

References

  • FDA prescribing information, semaglutide injection 2.4 mg (Wegovy): https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  • FDA prescribing information, tirzepatide injection (Zepbound): https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  • Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  • Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  • Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2022;327(14):1414-1425. https://jamanetwork.com/journals/jama/fullarticle/2789262
  • Sodhi M et al. Risk of biliary disease in patients taking GLP-1 agonists. JAMA Intern Med. 2023. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2797491
  • Davies M et al. Semaglutide dose response in people with obesity. Pubmed reference: https://pubmed.ncbi.nlm.nih.gov/34961259/
  • CDC National Center for Health Statistics, men and preventive care engagement: https://www.cdc.gov/nchs/data/series/sr_10/sr10_260.pdf
  • Hoffman SJ, Tan C. Following celebrities' medical advice: meta-narrative analysis. JAMA. 2013;310(14):1511-1512. https://jamanetwork.com/journals/jama/fullarticle/2712815